Skip to main content

Nice Research

Volume 409: debated on Friday 18 July 2003

The text on this page has been created from Hansard archive content, it may contain typographical errors.

To ask the Secretary of State for Health if he will make a statement on the National Institute for Clinical Excellence's research into the use of (a) clopidogrel and (b) dipyridamole for the prevention of (i) occlusive vascular and (ii) arterosclerotic events. [127032]

The National Institute for Clinical Excellence (NICE) is appraising the clinical and cost effectiveness of clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events. NICE expects to publish guidance in June 2004. Further details are available on NICE'S website at www.nice.org.uk